Research Analysts Offer Predictions for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research increased their FY2025 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Monday, February 2nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $6.01 per share for the year, up from their previous estimate of $5.91. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.86 EPS, Q1 2026 earnings at $1.42 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $2.38 EPS, FY2026 earnings at $7.43 EPS, Q2 2027 earnings at $2.02 EPS, Q3 2027 earnings at $1.99 EPS, Q4 2027 earnings at $2.54 EPS and FY2027 earnings at $8.18 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same quarter in the previous year, the company earned $1.27 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year.

Several other equities analysts also recently commented on HALO. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a research note on Tuesday, October 14th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Stock Up 0.6%

Shares of HALO opened at $78.42 on Wednesday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market capitalization of $9.22 billion, a PE ratio of 16.51, a P/E/G ratio of 0.32 and a beta of 0.97. The company’s 50-day simple moving average is $69.23 and its 200-day simple moving average is $68.91. Halozyme Therapeutics has a 1 year low of $47.50 and a 1 year high of $79.50.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the transaction, the director directly owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 71,398 shares of company stock valued at $5,170,152 in the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in HALO. Moran Wealth Management LLC lifted its holdings in Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 151 shares in the last quarter. Campbell Newman Asset Management Inc. increased its position in Halozyme Therapeutics by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after purchasing an additional 153 shares in the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 165 shares during the period. Alps Advisors Inc. raised its position in Halozyme Therapeutics by 3.0% in the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 170 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised a slate of quarterly and annual EPS estimates (notably Q1 2026 to $1.42 from $1.19, Q2 2026 to $1.80 from $1.49, Q3 2026 to $1.83 from $1.70, Q4 2026 to $2.38 from $1.84 and FY2026 to $7.43 from $6.22), signaling stronger expected profitability and supporting forward valuation. (summary of Zacks Research estimate updates)
• Positive Sentiment: An analyst raised Halozyme’s Q1 EPS forecast, which reinforces the near‑term beat narrative and likely contributed to buying interest. Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst
• Positive Sentiment: Zacks published a positive style/value write‑up describing HALO as a top long‑term value stock, which can attract value‑oriented and institutional buyers. Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Zacks trimmed its Q3 2027 estimate slightly (to $1.99 from $2.02); the change is minor relative to the larger upward revisions and unlikely to meaningfully reverse the positive sentiment unless further downgrades follow. (summary of Zacks Research estimate change)

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.